| Name | Shares allotted | % of global offering | % of post-IPO shares | Lock-up |
|---|---|---|---|---|
| 长兴兴长产业投资合伙企业(有限合伙) | 0 | 35.51% | — | 6 months |
| Rank | % of international placing | % of global offering |
|---|---|---|
| 前1名 | — | — |
The IPO of 同源康医药-B saw a modest oversubscription ratio of 2.29x, indicating subdued demand. The overall hit rate was 66.63%, meaning approximately two-thirds of valid applications were accepted, which is relatively high compared to typical Hong Kong IPOs. This reflects a less competitive environment. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
The last A-tier applicant (400,000 shares applied) received an expected allocation of only 0.33 lots, while the first B-tier applicant (500,000 shares) received exactly 1.0 lot. This sharp drop suggests an inefficient cliff-edge effect, making the A-tail highly unfavorable for small institutional or large retail investors. Broker fee per allocated lot would be disproportionately high for A-tail applicants compared to B-head. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Demographic data for this IPO is unavailable, with recorded totals and regional percentages all showing zero. Without information on mainland China participation or geographic distribution, no meaningful demographic analysis can be performed. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
This page shows allotment analysis for TYK Medicines-B (02410): one-lot hit rate, Pool A/B allotment distribution, oversubscription multiple, and grey-market and first-day performance. Data is parsed from the HKEX allotment results announcement. How allotment rates and clawback work is explained in How Hong Kong IPO Allotment Rates Work.

